))
#091: New treatment strategies in MS an ECTRIMS Special
Manage episode 454927640 series 3562061
Contenuto fornito da Nele Handwerker. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Nele Handwerker o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Learn more about new treatment for MS, focusing on innovative therapies like engineered vesicles, CAR-T, CD40L and high-dose vitamin D.
To read the full article visit my blog article: https://ms-perspektive.com/091-new-treatment-strategies
This time, I will present some studies on new treatment options for MS that show promising results and were presented at ECTRIMS 2024. Some candidates are not that new, such as high-dose vitamin D, but the key here is the long-term observation of a large number of MS patients under clearly defined conditions. Furthermore, there are engineered extracellular vesicles (EVs), CAR-T cell therapies and CD40L inhibitors such as frexalimab. These therapies represent a shift towards targeted treatments that aim to modulate the immune system in a more precise way, without the severe side effects of current medications. It’s about the research behind these novel approaches, their potential benefits, and the possibility of achieving better outcomes for patients, especially in the progressive stages of the disease. Listen to the episode or read the post to stay up to date on how these innovations could change the future of MS treatment.
Table of Contents- Why are new therapies important?
- Engineered small extracellular vesicles targeting regulatory T cells via CD40L signaling in multiple sclerosis
- Overview of CAR-T therapy in autoimmune diseases
- Future of new therapies in MS: CAR-T, CD40L and others
- Long-term outcomes of phase-1 study of neural stem cell transplantation in progressive multiple sclerosis
- High-dose cholecalciferol reduces multiple sclerosis disease activity after a clinically isolated syndrome : results of a 24-month placebo-controlled randomized trial (D-lay MS)
- Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension
See you soon and try to make the best out of your life, Nele
For more information and positive thoughts, subscribe to my newsletter for free.
Click here for an overview of all podcast episodes published so far.
85 episodi
Condividi
